Quote:

---

I have a hard time to see how one test can accurately measure density in all different tumors cancer cells , and CTC ..
Are we sure that every tumor cancers cell have same density ??
In HIV is different , person has same density , but in new produce , fast , abnormally growing cancer cells , I don’t know but I be surprise .

If this is true it is much more important Test than i even imagine.
And then why we will need escalating dose from 350 to 700 , only for safety ??

---

I believe the ultimate goal with cancer is 700mg. Having data with 350mg, 500mg and 700mg is required for safety. But they should get good data on how the ctc numbers drop vs dose. That data will be very valuable imo. It would be better data if it was random and they had a placebo to test against, but with deadly cancer, they can't do that. So this is the next best thing.


Assume they are going for 700mg, density with cancer probably not a concern. But the density of ccr5+ cancer cells might not even matter Quick math here and rough estimated here so it might be off but.

The measure the ccr5 density to estimate how much leronlimab is needed. But the missing piece that is not talked about, it depends on how many cells.

#cells x ccr5 density per cell = total number receptors to cover

T-cell count between 500 and 1,600 T-cells per cubic millimeter of blood

5 Liters of blood = 5,000,000 cubic millimeters of blood

So around 5 billion total T-Cells in the blood.

The number of ctc count is given by 7.5 ml of blood, a number of 5 or more being bad. So with 5 L of blood = 5000 ml, (5000/7.5) x 5= 3333 metastatic cancer cells.

So around 3000 cancer ctc cells vs 5 billion T-Cells in the blood. Of course the cancer sites matters, how big, etc, ccr5+, etc but my point is the T-Cell density might dominate.

But if it turn out it does matter, they could take a few measurements, and just use the the highest density recorded.